<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="/ProjectMundo/style/jats-html.xsl"?>
<!DOCTYPE response>
<article article-type="research-article" dtd-version="1.2" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">
    41467
   </journal-id>
   <journal-id journal-id-type="doi">
    10.1038/41467.2041-1723
   </journal-id>
   <journal-title-group>
    <journal-title>
     Nature Communications
    </journal-title>
    <abbrev-journal-title abbrev-type="publisher">
     Nat Commun
    </abbrev-journal-title>
   </journal-title-group>
   <issn pub-type="epub">
    2041-1723
   </issn>
   <publisher>
    <publisher-name>
     Nature Publishing Group UK
    </publisher-name>
    <publisher-loc>
     London
    </publisher-loc>
   </publisher>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">
    s41467-023-44276-x
   </article-id>
   <article-id pub-id-type="manuscript">
    44276
   </article-id>
   <article-id pub-id-type="doi">
    10.1038/s41467-023-44276-x
   </article-id>
   <article-categories>
    <subj-group subj-group-type="heading">
     <subject>
      Article
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/499
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /692/699/255/2514
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/326/596/4130
     </subject>
    </subj-group>
    <subj-group subj-group-type="SubjectPath">
     <subject>
      /631/326/596/2562
     </subject>
    </subj-group>
    <subj-group subj-group-type="TechniquePath">
     <subject>
      /141
     </subject>
    </subj-group>
    <subj-group subj-group-type="NatureArticleTypeID">
     <subject>
      article
     </subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">
     Risk of COVID-19 death in adults who received booster COVID-19 vaccinations in England
    </article-title>
   </title-group>
   <contrib-group>
    <contrib contrib-type="author" corresp="yes" id="Au1">
     <name name-style="western">
      <surname>
       Ward
      </surname>
      <given-names>
       Isobel L.
      </given-names>
     </name>
     <address>
      <email>
       Isobel.Ward@ons.gov.uk
      </email>
     </address>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
     <xref ref-type="corresp" rid="IDs4146702344276x_cor1">
      a
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au2">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-6848-5241
     </contrib-id>
     <name name-style="western">
      <surname>
       Robertson
      </surname>
      <given-names>
       Chris
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff2">
      2
     </xref>
     <xref ref-type="aff" rid="Aff3">
      3
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au3">
     <name name-style="western">
      <surname>
       Agrawal
      </surname>
      <given-names>
       Utkarsh
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au4">
     <name name-style="western">
      <surname>
       Patterson
      </surname>
      <given-names>
       Lynsey
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au5">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-1468-1823
     </contrib-id>
     <name name-style="western">
      <surname>
       Bradley
      </surname>
      <given-names>
       Declan T.
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff5">
      5
     </xref>
     <xref ref-type="aff" rid="Aff6">
      6
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au6">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-4101-4535
     </contrib-id>
     <name name-style="western">
      <surname>
       Shi
      </surname>
      <given-names>
       Ting
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au7">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0002-8553-2641
     </contrib-id>
     <name name-style="western">
      <surname>
       de Lusignan
      </surname>
      <given-names>
       Simon
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au8">
     <name name-style="western">
      <surname>
       Hobbs
      </surname>
      <given-names>
       F. D. Richard
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff4">
      4
     </xref>
     <xref ref-type="aff" rid="Aff8">
      8
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au9">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0001-7022-3056
     </contrib-id>
     <name name-style="western">
      <surname>
       Sheikh
      </surname>
      <given-names>
       Aziz
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff7">
      7
     </xref>
    </contrib>
    <contrib contrib-type="author" id="Au10">
     <contrib-id contrib-id-type="orcid">
      http://orcid.org/0000-0003-0160-217X
     </contrib-id>
     <name name-style="western">
      <surname>
       Nafilyan
      </surname>
      <given-names>
       Vahé
      </given-names>
     </name>
     <xref ref-type="aff" rid="Aff1">
      1
     </xref>
    </contrib>
    <aff id="Aff1">
     <label>
      1
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/021fhft25
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.426100.1
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2157 6840
      </institution-id>
      <institution content-type="org-name">
       Office for National Statistics
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Newport
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff2">
     <label>
      2
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/00n3w3b69
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.11984.35
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0001 2113 8138
      </institution-id>
      <institution content-type="org-division">
       Department of Mathematics and Statistics
      </institution>
      <institution content-type="org-name">
       Strathclyde University
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Glasgow
     </addr-line>
     <country country="GB">
      Scotland
     </country>
    </aff>
    <aff id="Aff3">
     <label>
      3
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/023wh8b50
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.508718.3
      </institution-id>
      <institution content-type="org-name">
       Public Health Scotland
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Glasgow
     </addr-line>
     <country country="GB">
      Scotland
     </country>
    </aff>
    <aff id="Aff4">
     <label>
      4
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/052gg0110
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.4991.5
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 8948
      </institution-id>
      <institution content-type="org-division">
       Nuffield Department of Primary Care Health Sciences
      </institution>
      <institution content-type="org-name">
       University of Oxford
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Oxford
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff5">
     <label>
      5
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/00hswnk62
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.4777.3
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0374 7521
      </institution-id>
      <institution content-type="org-division">
       Centre for Public Health
      </institution>
      <institution content-type="org-name">
       Queen’s University Belfast
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Belfast
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff6">
     <label>
      6
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/03ek62e72
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.454053.3
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 0494 5490
      </institution-id>
      <institution content-type="org-name">
       Public Health Agency
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Belfast
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff7">
     <label>
      7
     </label>
     <institution-wrap>
      <institution-id institution-id-type="ROR">
       https://ror.org/01nrxwf90
      </institution-id>
      <institution-id institution-id-type="GRID">
       grid.4305.2
      </institution-id>
      <institution-id institution-id-type="ISNI">
       0000 0004 1936 7988
      </institution-id>
      <institution content-type="org-division">
       Usher Institute
      </institution>
      <institution content-type="org-name">
       University of Edinburgh
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Edinburgh
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
    <aff id="Aff8">
     <label>
      8
     </label>
     <institution-wrap>
      <institution content-type="org-division">
       NIHR Applied Research Collaboration
      </institution>
      <institution content-type="org-name">
       Oxford Thames Valley
      </institution>
     </institution-wrap>
     <addr-line content-type="city">
      Oxford
     </addr-line>
     <country country="GB">
      UK
     </country>
    </aff>
   </contrib-group>
   <author-notes>
    <corresp id="IDs4146702344276x_cor1">
     <label>
      a
     </label>
     <email>
      Isobel.Ward@ons.gov.uk
     </email>
    </corresp>
   </author-notes>
   <pub-date date-type="pub" publication-format="electronic">
    <day>
     16
    </day>
    <month>
     1
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <pub-date date-type="collection" publication-format="electronic">
    <month>
     12
    </month>
    <year>
     2024
    </year>
   </pub-date>
   <volume>
    15
   </volume>
   <issue seq="398">
    1
   </issue>
   <elocation-id>
    398
   </elocation-id>
   <history>
    <date date-type="registration">
     <day>
      6
     </day>
     <month>
      12
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="received">
     <day>
      20
     </day>
     <month>
      7
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="accepted">
     <day>
      6
     </day>
     <month>
      12
     </month>
     <year>
      2023
     </year>
    </date>
    <date date-type="online">
     <day>
      16
     </day>
     <month>
      1
     </month>
     <year>
      2024
     </year>
    </date>
   </history>
   <permissions>
    <copyright-statement content-type="compact">
     © Crown 2024
    </copyright-statement>
    <copyright-year>
     2024
    </copyright-year>
    <copyright-holder>
     Crown
    </copyright-holder>
    <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
     <license-p>
      <bold>
       Open Access
      </bold>
      This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
      <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
       http://creativecommons.org/licenses/by/4.0/
      </ext-link>
      .
     </license-p>
    </license>
   </permissions>
   <abstract id="Abs1" xml:lang="en">
    <title>
     Chapisho
    </title>
    <p id="Par1">
     Ujumbe wa usafi wa COVID-19 kimekuwa muhimu sana kubadilisha mchakato wa pandemiki ya COVID-19. Kusimamia kuwa na usafi wa juu kwenye watu wenye ujasirikiano, usafi wa kibinafsi za COVID-19 katika UK imeundwa kulingana na umri na ujasirikiano wa kiafya. Tumeenda kufanya utafiti wa kohorti ya kibinadamu ya taarifa kwa taarifa za kibinafsi kutoka kwa hifadhi ya afya ya kibinafsi yanayohusishwa na taarifa za kibinafsi za 2021. Tumeleta modele za Cox ya sababu kusoma uhusiano kati ya matatizo ya kiafya na hatari ya kifo cha COVID-19 na kifo cha sababu nyingine kwa watu wazee wanaohusiana na umri 50-100 miaka katika Uingereza waliokuwa wamepewa usafi wa kibinafsi wa kibinafsi katika mwezi wa kasi ya 2022. Hapa tumeonyesha kuwa kuwa na ujasirikiano wa kumalizika au Down Syndrome (nisaba ya hatari=5.07;95% kipimo cha imani=3.69-6.98), usafi wa mifumo au fibrosis (2.88;2.43-3.40), usafi wa neuron wa kibinafsi, multiple sclerosis, myasthenia au Huntington’s disease (2.94, 1.82-4.74), usafi wa damu na mifumo ya kikapu (3.11;2.72-3.56), usafi wa kikapu (2.74;2.34-3.20), usafi wa kikapu au kipini (2.57;2.04 to 3.24), dementia (2.64;2.46 to 2.83) au usafi wa mifumo ya kikofu (2.65;1.95 to 3.59) ulikuwa na uhusiano na hatari ya kifo cha COVID-19. Watu wenye usafi wa damu au mifumo ya kikapu, usafi wa mifumo ya kikofu, cystic fibrosis, usafi wa mifumo au fibrosis, au usafi wa mifumo ya kikofu au systemic lupus erythematosus walikuwa na hatari ya kifo cha COVID-19 ya kubwa zaidi kulingana na sababu nyingine za kifo kulingana na watu walisio na matatizo haya. Wafanyiki wa siyasa wapasipo kujitolea watu wenye ujasirikiano kwa usafi wa kibinafsi za COVID-19 zinazofuata ili kusimamia hatari ya kifo cha COVID-19.
    </p>
   </abstract>
   <abstract abstract-type="ShortSummary" id="Abs2" xml:lang="en">
    <p id="Par2">
     Ward et al. utilise electronic health records to identify groups of adults (who had received a second booster dose of a COVID-19 vaccine) at elevated risk of COVID-19 death.
    </p>
   </abstract>
   <kwd-group kwd-group-type="hierarchical" vocab="FoR" vocab-identifier="ANZSRC 2008">
    <kwd content-type="term" vocab-term-identifier="11">
     Medical and Health Sciences
    </kwd>
    <nested-kwd>
     <kwd content-type="term" vocab-term-identifier="1117">
      Public Health and Health Services
     </kwd>
    </nested-kwd>
   </kwd-group>
   <custom-meta-group>
    <custom-meta>
     <meta-name>
      publisher-imprint-name
     </meta-name>
     <meta-value>
      Nature Portfolio
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-issue-count
     </meta-name>
     <meta-value>
      1
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-article-count
     </meta-name>
     <meta-value>
      398
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-pricelist-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-holder
     </meta-name>
     <meta-value>
      Springer Nature Limited
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-copyright-year
     </meta-name>
     <meta-value>
      2024
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-contains-esm
     </meta-name>
     <meta-value>
      Yes
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-year
     </meta-name>
     <meta-value>
      2023
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-month
     </meta-name>
     <meta-value>
      12
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-registration-date-day
     </meta-name>
     <meta-value>
      6
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      toc-levels
     </meta-name>
     <meta-value>
      0
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      volume-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-product
     </meta-name>
     <meta-value>
      NonStandardArchiveJournal
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      numbering-style
     </meta-name>
     <meta-value>
      Unnumbered
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-grants-type
     </meta-name>
     <meta-value>
      OpenChoice
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      metadata-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      abstract-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodypdf-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bodyhtml-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      bibliography-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      esm-grant
     </meta-name>
     <meta-value>
      OpenAccess
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      online-first
     </meta-name>
     <meta-value>
      false
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-file-reference
     </meta-name>
     <meta-value>
      BodyRef/PDF/41467_2023_Article_44276.pdf
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      pdf-type
     </meta-name>
     <meta-value>
      Typeset
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      target-type
     </meta-name>
     <meta-value>
      OnlinePDF
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      issue-type
     </meta-name>
     <meta-value>
      Regular
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      article-type
     </meta-name>
     <meta-value>
      OriginalPaper
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-primary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, Humanities and Social Sciences, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-secondary
     </meta-name>
     <meta-value>
      Science, multidisciplinary
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      journal-subject-collection
     </meta-name>
     <meta-value>
      Science (multidisciplinary)
     </meta-value>
    </custom-meta>
    <custom-meta>
     <meta-name>
      open-access
     </meta-name>
     <meta-value>
      true
     </meta-value>
    </custom-meta>
   </custom-meta-group>
  </article-meta>
 </front>
 <body>
  <sec id="Sec1" sec-type="introduction">
   <title>
    Tathmini
   </title>
   <p id="Par3">
    Ujumbe na kujitolea usafi wa kibinafsi ya COVID-19 yameongeza sana usafi wa COVID-19 wa kibinafsi, uchache na ukatili
    <sup>
     <xref ref-type="bibr" rid="CR1">
      1
     </xref>
    </sup>
    . Hata hivyo, kumi na kundi la watu walikuwa na hatari ya kubwa ya kifo cha COVID-19 bila kuzingatia kuwa walipewa usafi wa kibinafsi ya kwanza. Pia, umuhimu wa usafi wa kibinafsi imeonyesha kuongeza kulingana na muda
    <sup>
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
    </sup>
    . Kama hivyo, usafi wa kibinafsi za kujitolea zilizohitaji ili kusimamia kuwa na usafi wa kibinafsi ya kibinafsi kulingana na matokeo ya kibinafsi, hasa kulingana na kuondoka na masharti yanayosimamia uchache. Katika UK, usafi wa kibinafsi za kwanza za kujitolea zilizotolewa kwa kila mkuu mmoja mwezi tatu baada ya kuzingatia usafi wa kibinafsi ya pili ya COVID-19
    <sup>
     <xref ref-type="bibr" rid="CR3">
      3
     </xref>
    </sup>
    . Usafi wa kibinafsi za kujitolea zingine zilizotolewa kwa kundi la watu walio na hatari ya kubwa ya kujiingiza hospitali au kifo, kama vile watu wazee, watu wenye matatizo ya kiafya, au watu waliokuwa wamepata uhusiano na watu wenye ujasirikiano, kama vile wafanyi kiafya
    <sup>
     <xref ref-type="bibr" rid="CR4">
      4
     </xref>
    </sup>
    .
   </p>
   <p id="Par4">
    Kuendelea kusimamia watu wenye ujasirikiano kwa COVID-19 bado ni muhimu ili kusimamia athari za mara kwa mara na zinazohusu kwa mara nyingine za SARS-CoV-2 kwenye afya ya jamii na huduma za afya, hasa kulingana na watu wengi wanaotabasamu kwa usimamizi wa muda mrefu wa pandemiki ya COVID-19
    <sup>
     <xref ref-type="bibr" rid="CR5">
      5
     </xref>
    </sup>
    . Kujua watu wenye hatari ya kubwa ya matokeo ya kibinafsi kutoka kwa uchache wa SARS-CoV-2 ni muhimu ili kusimamia kuwa na usafi wa kibinafsi za kujitolea kwa wale wanaohitaji hilo wakati wa kusimamia gharama za programu ya usafi wa kibinafsi. Dalili zilizopo zinaonyesha kuwa kulingana na umri, kuwa na matatizo na matatizo maalum kama vile usafi wa mifumo ya kikofu (CKD) ina uhusiano na hatari ya kubwa ya kujiingiza hospitali na kifo kwa watu waliokuwa wamepewa usafi wa kibinafsi ya kibinafsi kamili na usafi wa kibinafsi ya kwanza ya kujitolea
    <sup>
     <xref ref-type="bibr" rid="CR6">
      6
     </xref>
    </sup>
    . Hata hivyo, kuna dalili kidogo kuhusu matatizo yanayohusiana na kifo cha COVID-19 kwa watu waliokuwa wamepewa usafi wa kibinafsi ya pili ya kujitolea katika mwezi wa kasi 2022 katika Uingereza. Kuelewa hatari kwa kundi la watu wengi ni muhimu ili kusimamia uamuzi wa JCVI katika UK na vikundi vingine vya kimataifa kuhusu usimamizi wa usafi wa kibinafsi za kujitolea zingine.
   </p>
   <p id="Par5">
    Katika utafiti huu, tulikuwa na matumaini ya kujua kundi la watu wazee waliokuwa wamepata hatari ya kubara ya kifo cha COVID-19, kati ya wale waliokuwa wamepewa usafi wa kibinafsi ya pili ya kujitolea kama sehemu ya kampani ya kujitolea ya mwezi wa kasi 2022 katika Uingereza. Tulitumia dataset ya yanayohusishwa na taarifa za kibinafsi ya 2021 yanayohusishwa na rekodi za kibinafsi ya kibinafsi na taarifa za kifo, tulipanga nisaba ya hatari ya kifo yanayohusishwa na COVID-19 kwa uwezo wa sifa na matatizo ya kiafya. Pia tulipanga nisaba ya hatari ya kifo yanayohusishwa na sababu nyingine za kifo, ili kuelewa kundi la watu walio na hatari ya kubara ya kifo cha COVID-19 lakini walikuwa wanao na hatari ya chache ya kifo kwa sababu nyingine
    <sup>
     <xref ref-type="bibr" rid="CR7">
      7
     </xref>
    </sup>
    .
   </p>
  </sec>
  <sec id="Sec2" sec-type="results">
   <title>
    Matokeo
   </title>
   <p id="Par6">
    Kuna watu 14,651,440 wazee wanaohusiana na umri 50-100 miaka katika kundi la utafiti wetu (mean = 67.9 miaka, standard deviation (SD) = 10.9); 46.9% walikuwa wanaume na 90.4% walikuwa wa kibritish. Sifa za kibinafsi za kundi la utafiti limejulikana katika Supplementary Data
    <xref ref-type="supplementary-material" rid="MOESM4">
     1
    </xref>
    <sup/>
    . Kati ya tarehe 1 Septemba 2022, na tarehe 11 Aprili 2023, kuna watu 6,800 waliokufa kwa sababu ya COVID-19 (52.2% wanaume), na 150,075 waliokufa kwa sababu nyingine za kifo, 1 (48.4% wanaume). Umri wa kibinafsi wa wale waliokufa kwa sababu ya COVID-19 ilikuwa 84.0 miaka (SD) = 8.87) na kwa wale waliokufa kwa sababu nyingine za kifo ilikuwa 82.3 miaka (SD = 9.85).
   </p>
   <p id="Par7">
    <fig id="Fig1" position="float">
     <label>
      Fig. 1
     </label>
     <caption xml:lang="sw">
      <title>
       Uhusiano kati ya umri na hatari ya kifo cha COVID-19.
      </title>
      <p>
       Nisabu za hatari (HRs) zilikuwa zimehisiwa kwa modele ya Cox regression iliyotengenezwa kulingana na umri, jinsia na muda. Nisaba ya hatari ya maelezo (HR) ni kwa mwanamke akiwa na umri wa 50 miaka. Matokeo ya COVID-19 yanayonyeshwa kwa rangi ya nyekundu na matokeo ya kifo cha sababu nyingine yanayonyeshwa kwa rangi ya blu. Nafasi inayofungwa nyuma ya mstari inayonyesha kipimo cha imani cha 95%.
      </p>
     </caption>
     <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-023-44276-x/41467_2023_44276_Fig1_HTML.png" mime-subtype="PNG" specific-use="web"/>
    </fig>
   </p>
   <p id="Par8">
    <fig id="Fig2" position="float">
     <label>
      Fig. 2
     </label>
     <caption xml:lang="sw">
      <title>
       Viwango vya hatari kwa kifo cha COVID-19 na kifo cha sababu nyingine kwa watu wamepewa usafi.
      </title>
      <p>
       Nisabu za hatari (HRs) zilikuwa zimehisiwa kwa modele ya Cox regression iliyotengenezwa kulingana na umri, jinsia, muda, utamaduni, eneo na sababu zote za afya (Model 5). Mstari zinazofungwa zinayonyesha nisaba ya hatari ya 1. Maelezo ya sababu zote ni kusio na matatizo ya sababu iliyotolewa. Matokeo ya COVID-19 yanayonyeshwa kwa rangi ya kijani na matokeo ya kifo cha sababu nyingine yanayonyeshwa kwa rangi ya nyampu. Nisaba ya hatari (HR) inayonyeshwa kwa nukta na mstari yanayonyesha kipimo cha imani cha 95%.
      </p>
     </caption>
     <graphic href="/ProjectMundo/MediaObjects/10X1038_s41467-023-44276-x/41467_2023_44276_Fig2_HTML.png" mime-subtype="PNG" specific-use="web"/>
    </fig>
   </p>
   <p id="Par9">
    Kuathiriwa na nisabu za hatari (HRs) za kifo cha COVID-19 na kifo cha sababu nyingine, tumeona kuwa kuna hatari ya kubwa zaidi ya kifo cha COVID-19 kulingana na kifo cha sababu nyingine kwa matatizo yanayofuata: usafi wa damu au mifumo ya kikapu, CKD, cystic fibrosis, usafi wa mifumo au fibrosis au rheumatoid arthritis au systemic lupus erythematosus (SLE) (Supplementary table
    <xref ref-type="supplementary-material" rid="MOESM1">
     2
    </xref>
    ). Kwa kinyume, tumeona kuwa hatari ya kifo cha sababu nyingine ilikuwa ya kubwa zaidi kulingana na kifo cha COVID-19 kwa dementia na usafi wa mifumo ya kikofu kulingana na watu walisio na matatizo haya.
   </p>
   <p id="Par10">
    Katika modeli ya kusaidia iliyo si ya kusimamia matatizo mengine ya kiafya, hatari ya matokeo ya COVID-19 ilikuwa ya kubuni zaidi kulingana na modeli iliyosimamia matatizo mengine (Supplementary Table
    <xref ref-type="supplementary-material" rid="MOESM1">
     3
    </xref>
    ). Kwa njia ya kina, kwa usafi wa kikapu katika modeli iliyosimamia matatizo mengine ya kiafya (Model 5) nisaba ya hatari (HR) ya matokeo ya COVID-19 ilikuwa chini ya 1 (HR:0.84;95%CI:0.77-0.95), lakini katika modeli ya kusaidia (iliyosimamia jinsia, umri, eneo, kundi la kiafya, na muda) hatari ilikuwa ya kubuni zaidi kwa watu walio hukumiwa na usafi wa kikapu kulingana na walisio (HR:1.22;95%CI:1.11-1.33) (Supplementary Table
    <xref ref-type="supplementary-material" rid="MOESM1">
     3
    </xref>
    ).
   </p>
  </sec>
  <sec id="Sec3" sec-type="discussion">
   <title>
    Mazungumzo
   </title>
   <p id="Par11">
    Uchunguzi huu wa taifa umetambua watu wazee wanaohusiana na hatari ya kubuni ya kifo cha COVID-19 baada ya kupewa usafi wa kibinafsi wa kibinafsi ya pili katika Uingereza katika mwezi wa kasi 2022. Matokeo yetu yanazama kuwa kuwa na ujasirikiano wa kumalizika au Down’s syndrome, usafi wa mifumo au fibrosis, usafi wa neuron wa kibinafsi, multiple sclerosis, myasthenia au Huntington’s disease, usafi wa damu na mifumo ya kikapu, usafi wa kikapu, usafi wa kikapu au kipini, dementia au usafi wa mifumo ya kikofu walikuwa wanaouhusiana na hatari ya kubuni ya kifo cha COVID-19. Kwa usafi wa damu au mifumo ya kikapu, CKD, cystic fibrosis, usafi wa mifumo au fibrosis au rheumatoid arthritis au SLE, uongezi wa hatari ya kubuni ulikuwa ya kubuni zaidi kwa kifo cha COVID-19 kulingana na kifo cha sababu nyingine. Matokeo yetu yanazama kuwa watu katika makundi haya walikuwa wanaoujasirikiano sana kwa kifo cha COVID-19 kulingana na sababu nyingine za kifo. Kwa mfano, kwa watu wenye rheumatoid arthritis au SLE, hatari ya kifo cha sababu nyingine ilikuwa si ya kubuni zaidi kulingana na watu walisio na matatizo haya; lakini, hatari ilikuwa ya kubuni zaidi kwa kifo cha COVID-19. Kwa muhimu, makundi haya hawalinikwa kama moja ya matatizo ya kiafya yanayohusiana na hatari ya juu ya kifo cha COVID-19, lakini tafsiri yetu yanazama kuhusu muhimu wa hatari ya kubuni kwa watu wanaoung’ezeka kufa kwa kifo cha COVID-19 kulingana na sababu nyingine.
   </p>
   <p id="Par12">
    Kwa matatizo mengi ya kiafya, uongezi wa hatari ya kifo cha COVID-19 ulikuwa sawa na, au chini ya, uongezi wa hatari ya kifo cha sababu nyingine, yanazama kuwa uongezi wa hatari ya kifo cha COVID-19 ulikuwa si tofauti na uongezi wa hatari ya kifo cha sababu nyingine. Ingawa tumeona kuwa watu wenye usafi wa kikapu walikuwa wanaoujasirikiano sana kwa kifo cha COVID-19 baada ya kuhakikisha umri, jinsia, kundi la kiafya, na eneo, tumeona kuwa kuwa na usafi wa kikapu halikuwa hanaouhusiana na hatari ya kifo cha COVID-19 baada ya kusimamia matatizo mengine, yanazama kuwa usafi wa kikapu halikuwa hanaouongeza hatari ya kifo cha COVID-19 kwa njia moja.
   </p>
   <p id="Par13">
    Matokeo yetu yanazama kusaidia utafiti ulioundwa kulingana na matokeo ya kifo baada ya kupewa usafi wa kibinafsi ya kibinafsi ya kwanza ya COVID-19
    <sup>
     <xref ref-type="bibr" rid="CR8">
      8
     </xref>
    </sup>
    . Kwa jumla, katika UK, usafi wa kibinafsi ya kibinafsi ya kwanza yameundwa kusimamia matokeo makali (hospitalisation na kifo), na makundi makali yamebaki na hatari ya kubuni
    <sup>
     <xref ref-type="bibr" rid="CR2">
      2
     </xref>
    </sup>
    . Watu wazee (zaidi ya miaka 80), wale wanaoujasirikiano na matatizo ya kiafya na matatizo makini kama CKD walikuwa wanaoujasirikiano sana. Uchunguzi ulioundwa katika Marekani ulirejelea kuwa kwa watafsiri walio wenye ujasirikiano wa kiafya, wanaodi, walio na CKD au usafi wa kikapu wa kikapu kawaida kuna uongezi wa hatari ya kutokea kwa COVID-19 ya kubuni kulingana na namba ya matatizo baada ya kupewa dozi mbili za kwanza
    <sup>
     <xref ref-type="bibr" rid="CR9">
      9
     </xref>
    </sup>
    . Ni muhimu kuhakikisha kuwa matokeo yanayotolewa katika utafiti wetu huwezi kurejelea tofauti za hatari ya kifo cha COVID-19 baada ya kujitambua. Utafiti wetu unazama kuhusu hatari ya kifo tangu muda wa kupewa usafi wa kibinafsi ya kibinafsi ya pili, si tangu kujitambua. Inawezekana kuwa hatari ya kujitambua kutokea kwa matatizo ya kiafya, kama watafsiri wanaoujasirikiano sana wawe na ujasirikiano wa kijamii kusimamia mizizi yao. Inawezekana pia kuwa watafsiri wanaoujasirikiano sana wawe na hatari ya kubuni zaidi kwa sababu wanaishi katika makazi ya kijamii au wana mazungumzo mengi na walezi au wafanyi kiafya.
   </p>
   <p id="Par14"/>
   <p id="Par15">
    Uchaguzi wetu una ngumu zana nyingi. Kwanza, tulitumia data ya kibinafsi ya Uingereza kutokana na usambazaji wa 2021 Census na rekodi za hifadhi ya afya ya kibinafsi. Sifa za kijamii na kijinsia, hasa kundi la kijinsia, iliyotolewa kutoka kwa 2021 Census, ilikuwa sahihi na ilikuwa na ukosefu chache, kama kubwa zaidi kulingana na baadhi ya rekodi za hifadhi ya afya ya kibinafsi ambazo kundi la kijinsia mara nyingi hutokea na si mara mara kujisajiliwa kwa mwanachama
    <sup>
     <xref ref-type="bibr" rid="CR10">
      10
     </xref>
    </sup>
    . Pili, tulitambua matatizo ya kiafya ya kuharibu kwa kutumia data ya huduma za kibinafsi ya kwanza. Tatu, tulitumia taarifa kuhusu sababu ya kifo kusimamia kifo cha COVID-19 na pia tulikuwa na uwezo wa kuchunguza kifo cha sababu nyingine za kifo kama mchakato wa usimbaji na kuhakikisha matatizo gani yalikuwa na hatari ya kubwa zaidi ya kifo cha COVID-19 kuliko kifo cha sababu nyingine za kifo.
   </p>
   <p id="Par16">
    Ukosefu muhimu wa uchaguzi wetu ni kutumia 2021 Census kwa kundi letu la watu, ambalo inamaanisha kuwa watu walisiojibu kwa Census walikuwa wamekuwa wamekosewa. Pia, ilikuwa na ukosefu wa walezi wa Census ambao hawakuweka kwenye huduma za taarifa ya kibinafsi (PDS). Hata hivyo, data zilizotumia zilikuwa na kusambaza 96.0% ya walezi waliopeana usafi wa kibinafsi ya kibinafsi katika Uingereza mwezi wa kasi wa 2022. Moja ya ukosefu wa kazi yetu ilikuwa ukosefu wa data kuhusu usambazaji wa hospitali za COVID-19
    <sup>
     <xref ref-type="bibr" rid="CR11">
      11
     </xref>
    </sup>
    . Ili kusimamia zana kwa kasi na kuelewa wakati gani wana hatari ya kubwa ya kuhudumika, kazi zinazofuata zinazopata data ya mara kwa mara zinapaswa kuhakikisha usambazaji wa hospitali. Pia, hatuwezi kuhakikisha tabia zinazoweza kujulikana kama zinazosimamia afya kama kuhakikisha ukosefu wa mazungumzo ya kijamii katika uchaguzi huu. Kwa hiyo, ni muhimu kujadili kwa baadhi ya wachezaji ambao hatari ya kuhudumika au kifo ilikuwa ya muhimu zaidi baada ya usimbaji wa SARS-CoV-2, wanaendelea kujisimamia ukosefu wa mazungumzo ya kijamii ili kusimamia wenyewe. Kwa hivyo, kwa wakati ambao hatari ilikuwa si ya kubwa ya matokeo ya COVID-19, lakini kwa jumla ilikuwa ya kubwa ya kifo cha sababu zote, tunapaswa kujitolea usafi wa kibinafsi kwa walezi hawa. Uchaguzi zinazofuata zinapaswa kujulikana matatizo ya kawaida (kama vile asthma) ili kuelewa kama mazungumzo kati ya kuwa na mshindi wa kawaida pamoja na mshindi mwingine wa kinafsi inatoa uwezekano wa kubwa ya matokeo mbaya za COVID-19.
   </p>
   <p id="Par17">
    Kazi yetu inachunguza hatari ya kifo cha sababu za COVID-19, pamoja na kifo cha sababu nyingine za kifo katika kohorti ya wakulima wanaohusiana na usafi wa kibinafsi ya kibinafsi mwezi wa kasi wa 2022. Ili kusimamia hatari ya COVID-19 kwa kasi, ni muhimu sana kujitolea walezi wanaohusiana na hatari ya kubwa zaidi ya kifo cha COVID-19. Tumeonyesha kuwa hatari ya kifo cha COVID-19, kulingana na kifo cha sababu nyingine, inabaki na kuwa ya kubwa zaidi sana kwa wakulima wenye ujasirikiano wa kumalizika au Down syndrome, usafi wa mifumo au fibrosis, usafi wa neuron wa kibinafsi, multiple sclerosis, myasthenia au Huntington’s disease, usafi wa damu na mifumo ya kikapu, usafi wa kikapu, usafi wa kikapu au kipini, dementia, au usafi wa mifumo ya kikofu. Walezi hawa wanaohusiana na mshindi hawapasipo kuwa muhimu kwa usafi wa kibinafsi zinazofuata, dawa, na mbinu mpya. Pia, tumeonyesha hatari ya kawaida ya matatizo ya kiafya na sifa za kijamii na kijinsia ambazo zinapaswa kujulikana na wafanyiki wa siyasa na watafariji kwa wakati wa kijamii ambao zinapaswa kujulikana kwa uchaguzi na usafi wa kibinafsi zinazofuata.
   </p>
  </sec>
  <sec id="Sec4" sec-type="methods">
   <title>
    Uchanganuzi
   </title>
   <p id="Par18">
    Uchaguzi huu ulipatikana na Uhusiano wa Etika ya Data wa Statistician wa Taifa (NSDEC) (UK Statistics Authority).
   </p>
   <sec id="Sec5">
    <title>
     Mapato ya taarifa
    </title>
    <p id="Par19"/>
   </sec>
   <sec id="Sec6">
    <title>
     Umoja wa utafiti
    </title>
    <p id="Par20"/>
   </sec>
   <sec id="Sec7">
    <title>
     Umuhimu
    </title>
    <p id="Par21">
     Matojo wa kwanza wa utafiti huu ulikuwa kifo cha COVID-19, uliyoelezwa kama kifo yoyote ya ICD yenye namba U07.1 na U07.2 iliyohifadhiwa kwenye sertifikia ya kifo, ambayo ilikuwa tayari kwa tarehe 11 Aprili 2023, na iliyohakikishwa kwa tarehe 26 Aprili 2023 (kukupa muda wa 15 siku kwa ajili ya hakikishwa ya kifo). Matojo wa pili ulikuwa kifo cha sababu zote zisizotokana na COVID-19
     <sup>
      <xref ref-type="bibr" rid="CR15">
       15
      </xref>
     </sup>
     .
    </p>
    <p id="Par22">
     Wanadamu walitabirika kuanzishwa 14 siku baada ya tarehe ya usafi wa kibinafsi wa kibinafsi ya mwezi wa kasi hadi tarehe 11 Aprili 2023. Muda wa hatari ulianzishwa 14 siku baada ya usafi wa kibinafsi na ulishuka kwa muda wa kifo (kama ni kifo cha COVID-19 au sababu nyingine), au mwisho wa utafiti (tarehe 11 Aprili 2023).
    </p>
   </sec>
   <sec id="Sec8">
    <title>
     Matatizo
    </title>
    <p id="Par23">
     Viwango vilivyotumika katika modeli vilikuwa viwango vya sifa kijamii na kijinsia kutoka kwa taarifa za 2021 na matatizo ya kiafya kutoka kwa taarifa za kibinafsi ya kibinafsi. Matatizo ya kiafya yalitolewa kwa kutumia taarifa za kibinafsi ya kibinafsi kutoka kwa huduma za kibinafsi ya kibinafsi (GPES) ya taarifa za Pandemic Planning and Research version 4 (GDPPR) kulingana na ufafanuzi ulioulizwa na modeli ya usimamizi wa hatari ya QCovid2, kwa kutumia taarifa kati ya tarehe 1 Machi 2015, na tarehe 21 Machi 2021 (tarehe ya taarifa). Modeli ya usimamizi wa hatari ya QCovid iliyotumika na NHS katika Great Britain kusimamia watu wanaotokana sana na hospitali za COVID-19 na kifo. Modeli iliyotathminiwa mara kwa mara kulingana na PHDA na taarifa kutoka kwa Scotland
     <sup>
      <xref ref-type="bibr" rid="CR16">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      <xref ref-type="bibr" rid="CR17">
       17
      </xref>
      <xref ref-type="bibr" rid="CR18">
       18
      </xref>
     </sup>
     . Viwango vyote vilivyotumika katika modeli vilivynyzwa kwenye Supplementary Data
     <xref ref-type="supplementary-material" rid="MOESM4">
      1
     </xref>
     <sup/>
     . Viwango vilivyosalia kwenye sifa za taarifa vilivyotolewa kwa kutumia imputation ya donor ya karibu zaidi, usulizi uliyotumika na ONS kwa kila viwango vya taarifa ya 2011. Taarifa yanayosalia kwenye Index ya Uzito wa Mifupa (BMI) iliyotumika kwa kutumia kategoria ya ‘Missing’.
    </p>
   </sec>
   <sec id="Sec9">
    <title>
     Uchanganuzi wa takwimu
    </title>
    <p id="Par24">
     Tumeleta regression ya Cox ya sababu kusoma uhusiano kati ya kila matatizo ya kiafya na hatari ya kifo cha COVID-19 na kifo cha sababu zote. Muda wa hatari ulianzishwa 14 siku baada ya pima ya usafi wa kibinafsi ya mwezi wa kasi na ulishuka kwa muda wa kifo au mwisho wa utafiti (tarehe 11 Aprili 2023). Kwa kila matojo (COVID-19 na non-COVID-19), tumeanza kuleta modeli iliyotumika kulingana na umri (restricted cubic spline na knots ya mwisho kwenye 5 na 95 percentile na 3 knots ndani), jinsia na muda wa mwaka (restricted cubic spline na knots ya mwisho kwenye 5 na 95 percentile na 3 knots ndani) (Model 1), kisha tulitakusanya kundi la kijinsia na eneo (Model 2), BMI (Model 3) na ujasirikiano (Model 4)
     <sup/>
     .
    </p>
    <p id="Par25">
     Kwa kila matatizo ya kiafya tumeleta modeli iliyotumika kulingana na matatizo yote ya kiafya ya QCovid, umri (spline), jinsia, muda wa mwaka (spline), kijinsia na eneo (Model 5). Kwa pamoja, tumeleta modele zingine kwa kila matatizo ya kiafya, iliyotumika kulingana na umri (restricted cubic spline), jinsia, muda wa mwaka (restricted cubic spline), kijinsia na eneo. Kwa sababu za hisabati, tahlili iliyofanyika kwenye taarifa yanayopanga kila mtu ambaye alikufa na sampuli ya 5% iliyotengenezwa ya wale ambao walikuwa wameisha hadi mwisho wa utafiti. Kusimamia tofauti za hatari kati ya modele za COVID-19 na non-COVID-19 kwa watu waliokuwa wamepewa matatizo ya kiafya, Z-statistics iliyohesabiwa kwa kila thamani kutoka kwa modele (Model 5) kwa kutumia taarifa iliyotengenezwa (1000 mara). Utengenezi wa taarifa uliyofanyika kwenye sampuli ya taarifa kusimamia upato wa matojo (kifo na wale ambao wameisha). Tahlili iliyofanyika kwa kutumia Spark version 2.4.0 na R version 3.5.1. Mataraka yote yamegunduliwa kwenye namba ya karibu 5, na vambo vinfra 10 vilivyoingizwa kwa sababu ya usimamizi wa taarifa.
    </p>
   </sec>
   <sec id="Sec10">
    <title>
     Ujumbe wa takwimu
    </title>
    <p id="Par26">
     Taarifa zaidi kuhusu mazungumzo ya utafiti inapatikana kwenye
     <xref ref-type="supplementary-material" rid="MOESM6">
      Nature Portfolio Reporting Summary
     </xref>
     iliyolinkwa kwenye makala hii.
    </p>
   </sec>
  </sec>
 </body>
 <back>
  <ack>
   <title>
    Usimamizi
   </title>
   <p>
    Waziri wanafurahisha Daniel Ayoubkhani kwa ujuzi wao wa takwimu na mawasiliano ya utafiti. Kazi hii imepewa pesa na UKRI kama sehemu ya anwani ya Chuo Kikuu cha Birmingham kwa COVID-19 National Core Studies (NCS), kwa “Phase 1 COVID-19 Immunity – National Core Study (Phase 1 IMM-NCS)”. Anwani ya anwani ya pesa ni MC_PC_20061.
   </p>
  </ack>
  <sec sec-type="author-contribution">
   <title>
    Sumbamizi ya waziri
   </title>
   <p>
    I.W., V.N. na A.S. walimeweka maelezo na kuanza utafiti. I.W. alahakikisha utafiti na kufanya takwimu takwimu, ambayo walikuwa wamechekwa na V.N., I.W., V.N., C.R., na A.S., waliongea kuhusu maelezo ya matokeo. I.W. na V.N. wameandaa maelezo ya awali. UA, LP, DB, TS, SdeL na RH wameongeza kuhusu kurekebisha na kuhakikisha maandishi na wamekubali maandishi ya mwisho.
   </p>
  </sec>
  <sec sec-type="peer-review">
   <title>
    Takwimu ya kibinafsi
   </title>
   <sec id="FPar1">
    <title>
     Takwimu ya kibinafsi
    </title>
    <p id="Par27">
     <italic>
      Nature Communications
     </italic>
     thanks the anonymous, reviewers for their contribution to the peer review of this work. A peer review file is available.
    </p>
   </sec>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Uradhi wa taarifa
   </title>
   <p>
    The source data used in this study is subject to controlled access due to its sensitive nature. All statistical data used in this study are available from the Office for National Statistics website.
    <xref ref-type="sec" rid="Sec12">
     Source data
    </xref>
    are provided with this paper.
   </p>
  </sec>
  <sec sec-type="data-availability">
   <title>
    Uradhi wa programu
   </title>
   <p>
    Code used in this study is available on Github [link]
   </p>
  </sec>
  <sec sec-type="ethics-statement">
   <sec id="FPar2" sec-type="COI-statement">
    <title>
     Matendo yanayechanganyika
    </title>
    <p id="Par28">
     SdeL has received University funding for vaccine related research from AstraZeneca, GSK, Moderna, Pfizer, Sanofi, Seqirus, and Takeda, and been advisory board members for AstraZeneca, GSK, Sanofi and Seqirus. The remaining authors declare no competing interests.
    </p>
   </sec>
  </sec>
  <ref-list id="Bib1">
   <title>
    Viungo vya kujadili
   </title>
   <ref-list>
    <ref id="CR1">
     <label>
      1.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Kerr
        </surname>
        <given-names>
         S
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales
      </article-title>
      <source>
       Int. J. Epidemiol.
      </source>
      <year>
       2023
      </year>
      <volume>
       52
      </volume>
      <fpage>
       22
      </fpage>
      <lpage>
       31
      </lpage>
      <pub-id pub-id-type="doi">
       10.1093/ije/dyac199
      </pub-id>
      <pub-id pub-id-type="pmid">
       36272418
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR2">
     <label>
      2.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Agrawal
        </surname>
        <given-names>
         U
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales
      </article-title>
      <source>
       Lancet
      </source>
      <year>
       2022
      </year>
      <volume>
       400
      </volume>
      <fpage>
       1305
      </fpage>
      <lpage>
       1320
      </lpage>
      <pub-id pub-id-type="doi">
       10.1016/S0140-6736(22)01656-7
      </pub-id>
      <pub-id pub-id-type="pmid">
       36244382
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9560746
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR3">
     <label>
      3.
     </label>
     <mixed-citation publication-type="other">
      Rough E., Coronavirus: Covid-19 booster vaccines frequently asked questions, 2022. [Online]. Available:
      <ext-link ext-link-type="uri" xlink:href="https://commonslibrary.parliament.uk/research-briefings/cbp-9332/">
       https://commonslibrary.parliament.uk/research-briefings/cbp-9332/
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR4">
     <label>
      4.
     </label>
     <mixed-citation publication-type="other">
      <italic>
       Greenbook Chapter:
      </italic>
      COVID-19 -
      <italic>
       SARS-CoV-2
      </italic>
      , no. April. 2023. [Online]. Available:
      <ext-link ext-link-type="uri" xlink:href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1153300/Greenbook-chapter-14a-26April2023.pdf">
       https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1153300/Greenbook-chapter-14a-26April2023.pdf
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR5">
     <label>
      5.
     </label>
     <mixed-citation publication-type="other">
      World Health Organization, Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic, May 2023. Avilable:
      <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic">
       https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR6">
     <label>
      6.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Agrawal
        </surname>
        <given-names>
         U
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57 million people in Scotland (EAVE II): a prospective cohort study,
      </article-title>
      <source>
       Lancet Respir. Med.
      </source>
      <year>
       2021
      </year>
      <volume>
       9
      </volume>
      <fpage>
       1439
      </fpage>
      <lpage>
       1449
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3MXitFOlsLvJ
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/S2213-2600(21)00380-5
      </pub-id>
      <pub-id pub-id-type="pmid">
       34599903
      </pub-id>
      <pub-id pub-id-type="pmcid">
       8480963
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR7">
     <label>
      7.
     </label>
     <mixed-citation publication-type="other">
      Office for National Statistics, Census 2021. Available:
      <ext-link ext-link-type="uri" xlink:href="https://census.gov.uk/">
       https://census.gov.uk/
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR8">
     <label>
      8.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Nafilyan
        </surname>
        <given-names>
         V
        </given-names>
       </name>
       <name>
        <surname>
         Ward
        </surname>
        <given-names>
         IL
        </given-names>
       </name>
       <name>
        <surname>
         Robertson
        </surname>
        <given-names>
         C
        </given-names>
       </name>
       <name>
        <surname>
         Sheikh
        </surname>
        <given-names>
         A
        </given-names>
       </name>
      </person-group>
      <article-title xml:lang="en">
       Evaluation of risk factors for postbooster Omicron COVID-19 deaths in England
      </article-title>
      <source>
       JAMA Netw. Open
      </source>
      <year>
       2022
      </year>
      <volume>
       5
      </volume>
      <fpage>
       E2233446
      </fpage>
      <pub-id pub-id-type="doi">
       10.1001/jamanetworkopen.2022.33446
      </pub-id>
      <pub-id pub-id-type="pmid">
       36074469
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9459656
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR9">
     <label>
      9.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Smits
        </surname>
        <given-names>
         PD
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities
      </article-title>
      <source>
       Vaccine
      </source>
      <year>
       2023
      </year>
      <volume>
       41
      </volume>
      <fpage>
       2447
      </fpage>
      <lpage>
       2455
      </lpage>
      <pub-id pub-id-type="doi">
       10.1016/j.vaccine.2023.02.038
      </pub-id>
      <pub-id pub-id-type="pmid">
       36803895
      </pub-id>
      <pub-id pub-id-type="pmcid">
       9933320
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR10">
     <label>
      10.
     </label>
     <mixed-citation publication-type="other">
      Office for National Statistics, Understanding consistency of ethnicity data recorded in health-related administrative datasets in England: 2011 to 2021, 2023.
      <ext-link ext-link-type="uri" xlink:href="https://www.ons.gov.uk/releases/understandingconsistencyofethnicitydatarecordedinhealthrelatedadministrativedatasetsinengland2011to2021">
       https://www.ons.gov.uk/releases/understandingconsistencyofethnicitydatarecordedinhealthrelatedadministrativedatasetsinengland2011to2021
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR11">
     <label>
      11.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Berec
        </surname>
        <given-names>
         L
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia
      </article-title>
      <source>
       PLoS One
      </source>
      <year>
       2022
      </year>
      <volume>
       17
      </volume>
      <fpage>
       1
      </fpage>
      <lpage>
       13
      </lpage>
      <pub-id pub-id-type="doi">
       10.1371/journal.pone.0270801
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR12">
     <label>
      12.
     </label>
     <mixed-citation publication-type="other">
      NHS, Personal Demographics Service. Available:
      <ext-link ext-link-type="uri" xlink:href="https://digital.nhs.uk/services/demographics">
       https://digital.nhs.uk/services/demographics
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR13">
     <label>
      13.
     </label>
     <mixed-citation publication-type="other">
      Office for National Statistics, Mortality statistics in England and Wales QMI, 2022. Available:
      <ext-link ext-link-type="uri" xlink:href="https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/methodologies/mortalitystatisticsinenglandandwalesqmi">
       https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/methodologies/mortalitystatisticsinenglandandwalesqmi
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR14">
     <label>
      14.
     </label>
     <mixed-citation publication-type="other">
      NHS England, The National Immunisation Management Service. Available:
      <ext-link ext-link-type="uri" xlink:href="https://www.england.nhs.uk/contact-us/privacy-notice/national-flu-vaccination-programme/#immunisation">
       https://www.england.nhs.uk/contact-us/privacy-notice/national-flu-vaccination-programme/#immunisation
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR15">
     <label>
      15.
     </label>
     <mixed-citation publication-type="other">
      World Health Organization, ICD-10 Version:2019. Available:
      <ext-link ext-link-type="uri" xlink:href="https://icd.who.int/browse10/2019/en#/U07.1">
       https://icd.who.int/browse10/2019/en#/U07.1
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR16">
     <label>
      16.
     </label>
     <mixed-citation publication-type="other">
      QCovid® risk calculator. Available:
      <ext-link ext-link-type="uri" xlink:href="https://www.qcovid.org/">
       https://www.qcovid.org/
      </ext-link>
     </mixed-citation>
    </ref>
    <ref id="CR17">
     <label>
      17.
     </label>
     <mixed-citation publication-type="journal">
      <person-group person-group-type="author">
       <name>
        <surname>
         Nafilyan
        </surname>
        <given-names>
         V
        </given-names>
       </name>
       <etal/>
      </person-group>
      <article-title xml:lang="en">
       An external validation of the QCovid risk prediction algorithm for risk of mortality from COVID-19 in adults: a national validation cohort study in England
      </article-title>
      <source>
       Lancet Digit. Heal.
      </source>
      <year>
       2021
      </year>
      <volume>
       3
      </volume>
      <fpage>
       e425
      </fpage>
      <lpage>
       e433
      </lpage>
      <pub-id assigning-authority="ChemPort ( Chemical Abstract Service )" pub-id-type="other">
       1:CAS:528:DC%2BB3sXis1SmsbY%3D
      </pub-id>
      <pub-id pub-id-type="doi">
       10.1016/S2589-7500(21)00080-7
      </pub-id>
     </mixed-citation>
    </ref>
    <ref id="CR18">
     <label>
      18.
     </label>
     <mixed-citation publication-type="other">
      Simpson C. R. et al. External validation of the QCovid risk prediction algorithm for risk of COVID-19 hospitalisation and mortality in adults: national validation cohort study in Scotland,
      <italic>
       Thorax
      </italic>
      , p. thoraxjnl-2021-217580, 2021,
      <ext-link ext-link-type="doi" xlink:href="10.1136/thoraxjnl-2021-217580">
       https://doi.org/10.1136/thoraxjnl-2021-217580
      </ext-link>
      .
     </mixed-citation>
    </ref>
   </ref-list>
  </ref-list>
  <app-group>
   <app id="App1" specific-use="web-only">
    <sec id="Sec11">
     <title>
      Viungo vya kujadili vya kubuni
     </title>
     <p id="Par29">
      <supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2023_44276_MOESM1_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Supplementary Information
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM2" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2023_44276_MOESM2_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Peer Review File
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM3" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2023_44276_MOESM3_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Description of Additional Supplementary Files
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM4" xlink:title="Supplementary information">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2023_44276_MOESM4_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Supplementary Data 1
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM5" xlink:title="Supplementary information">
       <media mime-subtype="vnd.ms-excel" mimetype="application" xlink:href="MediaObjects/41467_2023_44276_MOESM5_ESM.xlsx">
        <caption xml:lang="en">
         <p>
          Supplementary Data 2
         </p>
        </caption>
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="MOESM6" xlink:title="Supplementary information">
       <media mime-subtype="pdf" mimetype="application" xlink:href="MediaObjects/41467_2023_44276_MOESM6_ESM.pdf">
        <caption xml:lang="en">
         <p>
          Reporting Summary
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
    <sec id="Sec12">
     <title>
      Uradhi wa taarifa vya kubuni
     </title>
     <p id="Par30">
      <supplementary-material content-type="local-data" id="MOESM7" xlink:title="Source data">
       <media mime-subtype="plain" mimetype="text" xlink:href="MediaObjects/41467_2023_44276_MOESM7_ESM.csv">
        <caption xml:lang="en">
         <p>
          Source Data
         </p>
        </caption>
       </media>
      </supplementary-material>
     </p>
    </sec>
   </app>
  </app-group>
  <notes notes-type="ESMHint">
   <title>
    Viungo vya kujadili vya kubuni
   </title>
   <p>
    The online version contains supplementary material available at
    <ext-link ext-link-type="doi" xlink:href="10.1038/s41467-023-44276-x">
     https://doi.org/10.1038/s41467-023-44276-x
    </ext-link>
    .
   </p>
  </notes>
  <notes notes-type="Misc">
   <p>
    <bold>
     Publisher’s note
    </bold>
    Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
   </p>
  </notes>
 </back>
</article>
